BioLineRx Ltd.
BLRX · NASDAQ
11/24/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.00 | -0.04 | 1.19 |
| FCF Yield | 0.00% | -0.98% | -1.10% | -1.26% |
| EV / EBITDA | 0.00 | -6.73 | 42.21 | 221.99 |
| Quality | ||||
| ROIC | 0.00% | -7.05% | -6.91% | -15.53% |
| Gross Margin | 83.37% | 76.32% | 86.67% | 48.17% |
| Cash Conversion Ratio | 0.04 | -0.51 | 2.70 | 1.69 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,583,774.55% | 2,583,774.55% | 2,816,300.35% | 3,070,096.52% |
| Free Cash Flow Growth | 0.00% | 93.17% | 69.89% | 12.42% |
| Safety | ||||
| Net Debt / EBITDA | 0.00 | -1.55 | 0.82 | 1.49 |
| Interest Coverage | 0.00 | -8.34 | -5.69 | -1.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.03 | 0.01 | 1.94 |
| Cash Conversion Cycle | 0.00 | -685.56 | -2,969.65 | -6.44 |